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Transient expression assays using the reporter gene that encodes chloramphenicol acetyltransferase were
used to identify cis-acting sequences necessary for bovine immunodeficiency-like virus (BIY) transactivation.
Computer analyses identified two RNA stem-loop structures located immediately downstream of the transcrip-
tion start site in the long terminal repeat. Deletion analysis of the long terminal repeat indicated that sequences
containing the proximal stem-loop structure located between +4 and +31 are required for virus-specific
transactivation. Therefore, BIV likely utilizes a mechanism of transactivation similar to that of the human and
simian lentiviruses.
Bovine immunodeficiency-like virus (BIV) is a naturally
occurring lentivirus of cattle which is antigenically and
genetically related to other members of the lentivirus sub-
family of retroviruses, including human immunodeficiency
virus (HIV) and equine infectious anemia virus (EIAV) (23,
49). Lentiviruses are associated with a lifelong, persistent
infection and a chronic, variable disease course. The clinical
outcome of infection may depend, in part, on levels of viral
replication within cells of the immune system. Therefore,
understanding of the mechanisms by which various lentivi-
ruses are able to regulate their own replication is of interest
for identification of factors which contribute to clinical
disease and viral pathogenesis.
Lentiviruses encode a number of auxiliary proteins shown
to be important in the regulation of viral gene expression. All
of the lentiviruses characterized have been shown to encode
a viral transactivating protein, Tat, which increases the rate
of transcription of genes linked to the viral long terminal
repeat (LTR) (2-4, 16, 31, 35, 37, 43, 44, 46, 47). Interest-
ingly, the mechanisms of transactivation differ among vari-
ous members of the lentivirus subfamily. In HIV, EIAV, and
simian immunodeficiency virus, transactivation requires the
presence of a highly structured RNA sequence, termed the
transactivation-response region (TAR), located downstream
of the transcription initiation site (1, 3, 7, 12, 18-20, 28, 33).
In most cases, the LTRs exhibit relatively low levels of basal
activity yet are highly activated in the presence of homolo-
gous Tat (14, 16, 42). In contrast, LTR sequences required
for transactivation by visna virus and feline immunodefi-
ciency virus (FIV) are located in the U3 region of the LTR
and include AP-1 and AP-4 enhancer sequences (32, 47).
Both visna virus and FIV LTRs exhibit a high level of basal
activity in most cell types but are weakly transactivated (15,
31, 47). At the protein level, the HIV and simian immuno-
deficiency virus Tat proteins contain highly conserved func-
tional domains, which include a cysteine-rich domain, a
highly basic domain, and a conserved core region (14, 21, 26,
27, 29, 41). EIAV Tat lacks the cysteine-rich domain but
retains a conserved core region as well as a highly basic
* Corresponding author.
domain (17, 48). Similar, functionally analogous domains are
absent in the transactivating protein of visna virus (15, 25),
as well as in the putative FIV Tat protein (36, 47).
The regulatory mechanisms of BIV are less well charac-
terized. BIV has been found to encode a transacting protein
derived from an open reading frame located in the pol-env
intragenic region (35, 37). However, the cis-acting sequences
in the LTR required for transactivation have not been
identified. The BIV LTR is a relatively strong promoter in
some cell types and is poorly transactivated in the presence
of virus in these cells (37). This indicates that transactivation
by BIV may be mechanistically similar to that of visna virus
and FIV. However, the Tat protein of BIV is structurally
more analogous to primate Tat proteins and contains the
cysteine, core, and basic functional domains (22, 35). More-
over, computer analysis of the BIV RNA for the presence of
TAR-like secondary structures in the 5' end identified two
potential stem-loop structures between nucleotides +4 and
+69 (Fig. 1B). The structure of BIV Tat and the presence of
a TAR-like element in the extreme 5' end of the BIV RNA
are highly suggestive that viral transactivation is mediated
through an RNA enhancer similar to those of EIAV and
primate lentiviruses. To test this hypothesis, we created a
series of deletion and substitution mutations in the BIV LTR
and used transient expression assays to examine the effects
of these mutations on viral transactivation.
Previous studies have demonstrated that in certain cell
types, the BIV LTR is a relatively strong promoter but is
weakly transactivated in the presence of virus or BIV Tat
(35, 37). Therefore, we chose to use MDBK cells, in which
the basal promoter activity is low. All assays were done with
uninfected MDBK cells (ATCC CCL22) and MDBK/BIV26,
a clonal cell line derived from MDBK cells chronically
infected with the R29 isolate of BIV (49, 51). To establish the
clonal cell line, persistently infected MDBK cells were
seeded in 100-mm-diameter tissue culture dishes at 10 to 100
cells per dish. After 10 to 14 days in culture, individual cell
clones were removed and expanded in 24-well tissue culture
plates. Following expansion, culture medium was tested for
the presence of reverse transcriptase activity as previously
described (8). In addition, the cells were screened for the
presence of BIV and bovine viral diarrhea virus by using a
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FIG. 1. (A) Nucleotide sequence of the BIV LTR cloned from MDBK cells persistently infected with the R29 isolate of BIV. The U3, R,
and U5 borders are based on a report by Garvey et al. (22). The sequence is numbered with reference to the transcription initiation site (+ 1)
(22). The locations of potential promoter and enhancer sequences are indicated by open boxes (CAAT and TATAA) or by underlines. The
positions of restriction enzyme sites used in subcloning are shown. (B) Secondary-structure model of predicted TAR sequence of BIV. The
structure was generated by using the RNA Fold program and PC Gene Sequence Analysis software with a maximum distance of 100
nucleotides between base pairs. The free energy of the structure is -88.7 kcal/mol (1 cal = 4.184 J).
focal immunoassay similar to those previously described (9,
10, 13, 45). A bovine viral diarrhea virus-free clonal cell line,
designated MDBK/BIV26, was found to be BIV positive by
both immunofluorescence and reverse transcriptase activity
and was used for transient expression studies. All cells were
propagated in Dulbecco's minimum essential medium sup-
plemented with antibiotics, 10% fetal calf serum, and 1%
newborn bovine serum.
The complete BIV LTR (11) was inserted at the HindIII
site into expression plasmid pCATBASIC (Promega Biotec,
Madison, Wis.), upstream of the gene for bacterial chloram-
phenicol acetyltransferase (CAT). To generate 3' deletions
(p3D series), pBIVLTRCAT was digested with XhoI and
SphI, removing 63 nucleotides from the 3' end of the LTR
(Fig. 1A). A series of deletions in which progressively more
of the sequence was removed from the 3' end of the LTR
was then generated by the method of Henikoff (30). For
construction of 5' deletions, pBIVLTRCAT was cut with
HindIII to remove the entire LTR. The vector DNA was
treated with Klenow to create blunt ends and then cut with
SalI. To create a nested set of U3 deletions, the LTR insert
was digested with selected restriction enzymes which cut in
the U3 region of the BIV LTR (Fig. 1A), including BamHI
(-319), AccI (-207), NsiI (-115), and AciI (-74). The ends
were filled in with Klenow, and the DNAs were digested
with XhoI (+140) and inserted into the SalI-digested expres-
sion vector. In each case, the XhoI-SalI cohesive ends
ensured insertion of the LTR fragment in the correct orien-
tation. All clones were verified by DNA sequencing.
Comparison of transactivation among the deletion mutants
indicated that sequences between -76 and +54 are required
for transactivation (Fig. 2). This region encompasses the
TATAA box at -25 and the 5'-proximal stem-loop at +4 to
+31 and extends into the distal stem-loop at +32 to +69.
Transactivation was completely abolished in constructs
p3D+ 12, p3D+ 19, and p3D+26. These constructs retain the
TATAA box and sequences upstream of the transcription
start site but lack sequences required to form the proximal
stem-loop structure. These results indicated that BIV trans-
activation requires the presence of sequences downstream of
the transcription initiation site, including the presence of the
potential RNA stem-loop structure located at +4 to +31.
Transactivation was reduced to 60% of wild-type levels in
p3D+54 (Fig. 2), suggesting that the second stem-loop
structure between +32 and +69 contributes to transactiva-
tion. The predicted secondary structure of the BIV LTR is
most similar to those of HIV type 2 (HIV-2) and simian
immunodeficiency virus insofar as there are multiple stem-
loops (1, 3, 19, 20). The roles of additional stem-loop
structures in transactivation are not well characterized.
Deletion analysis of the HIV-2 LTR has shown that the
proximal loop is sufficient for transactivation (20). Muta-
tional analysis of HIV-2 TAR indicated that distal loop 2
does play a role in viral transactivation; however, the
contribution of loop 2 was masked in the presence of an
intact wild-type loop 1 (20). Although our data indicate that
BIV loop 1 is sufficient for optimal CAT activity, a role for
loop 2 in transactivation is suggested by a reported three- to
sixfold reduction in BIV transactivation when the LTR is
deleted downstream of +64 (35). Interestingly, disruption of
the predicted structure of loop 2 in p3D+54 resulted in an
increase in CAT activity in both MDBK and MDBK/BIV26
cells. This suggests that the secondary structure of the distal
stem-loop plays a role in translational regulation, perhaps by
making the RNA less accessible to ribosome binding. Previ-
ous studies have found that disruption of the secondary
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mIzzIU3
CAAT TATAA
Percent Conversion
MDBK MDBK/BIV26
0.23 0.06
0.33 ± 0.06
0.20 ± 0.00
0.50 ± 0.44
0.17 ± 0.06
0.27 ± 0.06
0.23 ± 0.06
0.17 ± 0.15
0.23 ± 0.15
0.27 ± 0.15
0.30 ± 0.01
0.27 ± 0.06
10.60 ± 3.88
15.57 ± 5.00
11.33 ± 3.42
17.67 ± 3.21
0.30 ± 0.00
0.40 ± 0.00
0.33 ± 0.06
0.27 ± 0.06
6.37 ± 1.34
12.37 ± 1.94
17.63 ± 1.98
13.97 ± 3.11
FIG. 2. Deletion analysis of the BIV LTR showing CAT activity in uninfected MDBK cells and in MDI3K/BIV26, a clonal cell line
persistently infected with the R29 isolate of BIV. The structure of the full-length LTR is shown at the top, and the locations of the U3, R,
and U5 regions (22) and CAAT and TATAA motifs are indicated. Sequences retained in the truncated plasmids are represented by solid lines.
The 5'- or 3'-terminal nucleotide is indicated for each truncation and is numbered with respect to the transcription start site (+1). MDBK and
MDBK/BIV26 were transfected with 2 p.g of reporter plasmid DNA by calcium phosphate-mediated transfection (24). At 48 h following
transfection, cells were harvested and lysed by three rounds of freeze-thawing, and the protein concentration of each lysate was determined
by the bicinchoninic acid method (Pierce). CAT activity was determined by using 20 pLg of lysate and previously described procedures (24).
Results are given as percentages of [14C]chloramphenicol converted to its acetylated form and are means of three transfections the standard
errors of the means. Fold transactivation was determined by using the mean percent conversion in MDBK/BIV compared with the mean value
in uninfected MDBK cells.
structure of HIV-1 increases binding to initiation factor
eIF-4B (38). Similarly, mRNAs containing a spliced TAR of
simian immunodeficiency virus, with simpler and less stable
secondary structures, are more efficiently translated than are
mRNAs containing a highly structured, unspliced TAR (50).
A more precise delineation of the contribution of loops 1 and
2 in BIV transactivation requires a detailed mutational
analysis of the stem-loop structures.
The BIV LTR contains several enhancer sites in the U3
region (22) (Fig. 1A), and a series of 5' deletion plasmids was
generated to determine the role of U3 elements in Tat-
mediated transactivation. The most significant change was
an approximately 40% decrease in transactivation in p5D-74
(Fig. 2), indicating that sequences between -115 and -74
are required for maximum virus transactivation. p5D-74
retains three potential SP-1 sites (Fig. 1A) but lacks the
CAAT enhancer motif (Fig. 1A). Restoration of the CAAT
motif in p5D-115 resulted in levels of transactivation com-
parable to that of the wild type. Thus, optimum BIV trans-
activation required the presence of upstream enhancer mo-
tifs, similar to HIV-1 Tat (6). Deletion of enhancer elements
further upstream, including the NF-KB and AP-1 sites, did
not greatly affect BIV transactivation (Fig. 2). However, one
deletion construct, p5D-207, did show an increase in trans-
activation. Negative regulatory elements have been found
previously in a number of lentivirus LTRs, including EIAV
(18) and HIV-1 (39), and it is possible that the BIV LTR
contains a similar negative regulatory element located be-
tween -207 and -319.
Several structural and spatial features are required for
optimal transactivation of the HIV-1 TAR, including the
presence of a base-paired stem structure (7, 28, 40), as well
as specific nucleotides within both the bulge and the loop (5,
19, 40). The latter includes a CUG sequence which is
conserved in primate lentiviruses, as well as in EIAV (5, 12,
19). Examination of specific nucleotide sequences within the
bulge and loop of BIV identified several differences between
BIV and primate lentiviruses which might affect overall
levels of transactivation. These included potential base
pairing within the BIV bulge, as well as the absence of a
CUG sequence in loop 1. A limited number of BIV TAR
mutations were analyzed to determine whether levels of BIV
transactivation could be increased over that observed in the
wild-type LTR.
The trinucleotide bulge sequence in each of the predicted
stem-loops of the BIV LTR contains the requisite uridine in
the correct position. However, the structure of the bulge in
the proximal stem-loop may be compromised by potential
base pairing of the middle guanidine in the UGU bulge with
a cytidine at +25. To determine whether elimination of the
base pairing would increase BIV transactivation, the G at
+11 was mutated to a C (Fig. 3). Rather than increasing
transactivation, this single nucleotide change reduced trans-
activation by 60%. These results suggest that the secondary
structure in the UGU bulge is sufficient for Tat-TAR inter-
action and, moreover, that specific nucleotides within the
TAR bulge are required for optimal transactivation. To
explore the role of specific sequences within the BIV TAR
loop, we generated a BIV construct containing a CUG
sequence in loop 1. This change resulted in only a slight
increase in levels of transactivation (Fig. 3). Other studies
have found that transactivation by HIV-1 Tat can be highly
sensitive to point mutations in the loop region (5, 19), and the
absence of either a significant increase, or decrease, in
transactivation mediated by the altered BIV loop sequence
was somewhat surprising. More extensive mutational anal-
yses of the BIV TAR are required to fully delineate the role
of specific nucleotides in BIV transactivation.
In the present study, we showed that transactivation by
BIV requires the presence of sequences downstream of the
transcription initiation site predicted to contain an RNA
stem-loop structure highly analogous to the TAR structure of
primate lentiviruses. Although the data did not establish
whether the BIV TAR structure acts as an RNA or a DNA
pBIVLTR
p3D+140
p3D+78
p3D+54
p3D+26
p3D+19
p3D+12
p3D-23
p5D-74
p5D-115
p5D-207
p5D-319
Fold
Transactivation
46.09
47.18
56.65
35.34
1.76
1.48
1.43
1.59
27.69
45.81
58.77
51.74
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G C
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MDBK/BIV26 9.93 ± 2.48
Fold Transactivation 43.17
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C U
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CG
G C
A U
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G C
CG
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CG
G C
A U
UUC C
+1 +32
Bulge C
0.30 ± 0.17
5.27 ± 1.68
17.57
FUG
c u
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CG
G C
AU
U
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U
G C
CG
UA
CG
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A U
UUC C
+1 +32
Loop CUG
0.25 + 0.07
11.60 ± 0.85
46.40
FIG. 3. Effects of point mutations within the bulge-and-loop
sequence of TAR on BIV transactivation. A BglII site was intro-
duced into p3D+ 140 just upstream of the TAR sequence by muta-
tion of bases -8 to -10 by using standard oligonucleotide-directed
mutagenesis methods (34). The resulting plasmid, pBIVLTRB-
glCAT, has a TAR sequence flanked by BglII and Sacl restriction
sites. Thus, this TAR cassette can be replaced readily with synthetic
oligonucleotides, enabling introduction of specific mutations (open
box). Oligonucleotides containing specific mutations in the TAR
loop (loop CUG) and bulge (bulge C) were synthesized and inserted
into pBIVLTRBglCAT. Bulge C contains a G-to-C point mutation at
+11, while loop CUG contains an AU-to-UG substitution at +18
and +19. Plasmid DNA was isolated from selected colonies and
sequenced to verify the point mutations. MDBK and MDBK/BIV26
cells were transfected, and CAT activity was determined as de-
scribed in legend to Fig. 2. Results are expressed as mean values of
three transfections + the standard errors of the means.
element, taken together with the structural similarities
among the BIV and primate lentivirus Tat proteins, these
findings indicate that the mechanism of BIV transactivation
is similar to that of primate lentiviruses. Interestingly, there
does not appear to be a correlation between the clinical-
pathological signs of lentivirus infection and the mechanism
of viral transactivation. Primate and feline lentiviruses rep-
licate in CD4+ cells and are associated with severe immu-
nosuppression and AIDS. The pathogenesis of BIV is less
well characterized, although there is some evidence of early
lymphoid changes characteristic of immunodeficiency vi-
ruses (11). In contrast, visna virus and EIAV replicate solely
in cells of the monocyte-macrophage lineage and are not
associated with an immunodeficiency syndrome. In terms of
transactivation, however, FIV is most similar to visna virus
and caprine arthritis-encephalitis virus, whereas BIV and
EIAV are mechanistically similar to the primate immunode-
ficiency viruses. A thorough understanding of both the
similarities and the differences among lentiviruses in the
mechanisms that control viral replication may help to iden-
tify key events that contribute to the alternate disease
courses.
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